Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.

Arendse LB, Danser AHJ, Poglitsch M, Touyz RM, Burnett JC Jr, Llorens-Cortes C, Ehlers MR, Sturrock ED.

Pharmacol Rev. 2019 Oct;71(4):539-570. doi: 10.1124/pr.118.017129. Review.

PMID:
31537750
2.

The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders.

Marsault E, Llorens-Cortes C, Iturrioz X, Chun HJ, Lesur O, Oudit GY, Auger-Messier M.

Ann N Y Acad Sci. 2019 Jun 25. doi: 10.1111/nyas.14123. [Epub ahead of print]

PMID:
31236974
3.

Orally Active Aminopeptidase A Inhibitor Prodrugs: Current State and Future Directions.

Keck M, Hmazzou R, Llorens-Cortes C.

Curr Hypertens Rep. 2019 May 21;21(7):50. doi: 10.1007/s11906-019-0957-4. Review.

PMID:
31115779
4.

NI956/QGC006, a Potent Orally Active, Brain-Penetrating Aminopeptidase A Inhibitor for Treating Hypertension.

Keck M, De Almeida H, Compère D, Inguimbert N, Flahault A, Balavoine F, Roques B, Llorens-Cortes C.

Hypertension. 2019 Jun;73(6):1300-1307. doi: 10.1161/HYPERTENSIONAHA.118.12499.

PMID:
31067198
5.

A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension.

Azizi M, Courand PY, Denolle T, Delsart P, Zhygalina V, Amar L, Lantelme P, Mounier-Vehier C, De Mota N, Balavoine F, Llorens-Cortes C.

J Hypertens. 2019 Aug;37(8):1722-1728. doi: 10.1097/HJH.0000000000002092.

PMID:
30882604
6.

Plasma kallikrein cleaves and inactivates apelin-17: Palmitoyl- and PEG-extended apelin-17 analogs as metabolically stable blood pressure-lowering agents.

Fischer C, Lamer T, Wang W, McKinnie SMK, Iturrioz X, Llorens-Cortes C, Oudit GY, Vederas JC.

Eur J Med Chem. 2019 Mar 15;166:119-124. doi: 10.1016/j.ejmech.2019.01.040. Epub 2019 Jan 18.

PMID:
30690406
7.

Brain renin-angiotensin system blockade with orally active aminopeptidase A inhibitor prevents cardiac dysfunction after myocardial infarction in mice.

Boitard SE, Marc Y, Keck M, Mougenot N, Agbulut O, Balavoine F, Llorens-Cortes C.

J Mol Cell Cardiol. 2019 Feb;127:215-222. doi: 10.1016/j.yjmcc.2018.12.008. Epub 2018 Dec 30.

PMID:
30599150
8.

Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction.

Leenen FHH, Ahmad M, Marc Y, Llorens-Cortes C.

J Cardiovasc Pharmacol. 2019 Feb;73(2):82-91. doi: 10.1097/FJC.0000000000000638.

PMID:
30531435
9.

Central antihypertensive effects of chronic treatment with RB150: an orally active aminopeptidase A inhibitor in deoxycorticosterone acetate-salt rats.

Marc Y, Hmazzou R, Balavoine F, Flahault A, Llorens-Cortes C.

J Hypertens. 2018 Mar;36(3):641-650. doi: 10.1097/HJH.0000000000001563.

PMID:
28968260
10.

Involvement of arginine 878 together with Ca2+ in mouse aminopeptidase A substrate specificity for N-terminal acidic amino-acid residues.

Couvineau P, de Almeida H, Maigret B, Llorens-Cortes C, Iturrioz X.

PLoS One. 2017 Sep 6;12(9):e0184237. doi: 10.1371/journal.pone.0184237. eCollection 2017.

11.

Synthetic Modification within the "RPRL" Region of Apelin Peptides: Impact on Cardiovascular Activity and Stability to Neprilysin and Plasma Degradation.

McKinnie SMK, Wang W, Fischer C, McDonald T, Kalin KR, Iturrioz X, Llorens-Cortes C, Oudit GY, Vederas JC.

J Med Chem. 2017 Jul 27;60(14):6408-6427. doi: 10.1021/acs.jmedchem.7b00723. Epub 2017 Jul 7.

PMID:
28685579
12.

Role of the Vasopressin/Apelin Balance and Potential Use of Metabolically Stable Apelin Analogs in Water Metabolism Disorders.

Flahault A, Couvineau P, Alvear-Perez R, Iturrioz X, Llorens-Cortes C.

Front Endocrinol (Lausanne). 2017 May 31;8:120. doi: 10.3389/fendo.2017.00120. eCollection 2017. Review.

13.

A Time-Resolved FRET Cell-Based Binding Assay for the Apelin Receptor.

Valencia C, Dujet C, Margathe JF, Iturrioz X, Roux T, Trinquet E, Villa P, Hibert M, Dupuis E, Llorens-Cortes C, Bonnet D.

ChemMedChem. 2017 Jun 21;12(12):925-931. doi: 10.1002/cmdc.201700106. Epub 2017 Apr 20.

PMID:
28374567
14.

Development of original metabolically stable apelin-17 analogs with diuretic and cardiovascular effects.

Gerbier R, Alvear-Perez R, Margathe JF, Flahault A, Couvineau P, Gao J, De Mota N, Dabire H, Li B, Ceraudo E, Hus-Citharel A, Esteoulle L, Bisoo C, Hibert M, Berdeaux A, Iturrioz X, Bonnet D, Llorens-Cortes C.

FASEB J. 2017 Feb;31(2):687-700. doi: 10.1096/fj.201600784R. Epub 2016 Nov 4.

PMID:
27815337
15.

Angiotensin-Converting Enzyme 2 Metabolizes and Partially Inactivates Pyr-Apelin-13 and Apelin-17: Physiological Effects in the Cardiovascular System.

Wang W, McKinnie SM, Farhan M, Paul M, McDonald T, McLean B, Llorens-Cortes C, Hazra S, Murray AG, Vederas JC, Oudit GY.

Hypertension. 2016 Aug;68(2):365-77. doi: 10.1161/HYPERTENSIONAHA.115.06892. Epub 2016 May 23.

PMID:
27217402
16.

Plasma Apelin Concentrations in Patients With Polyuria-Polydipsia Syndrome.

Urwyler SA, Timper K, Fenske W, de Mota N, Blanchard A, Kühn F, Frech N, Arici B, Rutishauser J, Kopp P, Stettler C, Müller B, Katan M, Llorens-Cortes C, Christ-Crain M.

J Clin Endocrinol Metab. 2016 May;101(5):1917-23. doi: 10.1210/jc.2016-1158. Epub 2016 Mar 11.

PMID:
26967692
17.

Convenient Access to Fluorescent Probes by Chemoselective Acylation of Hydrazinopeptides: Application to the Synthesis of the First Far-Red Ligand for Apelin Receptor Imaging.

Margathe JF, Iturrioz X, Regenass P, Karpenko IA, Humbert N, de Rocquigny H, Hibert M, Llorens-Cortes C, Bonnet D.

Chemistry. 2016 Jan 22;22(4):1399-405. doi: 10.1002/chem.201503630. Epub 2015 Dec 18.

PMID:
26682530
18.

Directed Molecular Evolution of an Engineered Gammaretroviral Envelope Protein with Dual Receptor Use Shows Stable Maintenance of Both Receptor Specificities.

Friis KP, Iturrioz X, Thomsen J, Alvear-Perez R, Bahrami S, Llorens-Cortes C, Pedersen FS.

J Virol. 2015 Nov 25;90(3):1647-56. doi: 10.1128/JVI.02013-15. Print 2016 Feb 1.

19.

[Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension].

Llorens-Cortès C.

Biol Aujourdhui. 2014;208(3):217-24. doi: 10.1051/jbio/2014010. Epub 2014 Dec 5. Review. French.

PMID:
25474003
20.

New structural insights into the apelin receptor: identification of key residues for apelin binding.

Gerbier R, Leroux V, Couvineau P, Alvear-Perez R, Maigret B, Llorens-Cortes C, Iturrioz X.

FASEB J. 2015 Jan;29(1):314-22. doi: 10.1096/fj.14-256339. Epub 2014 Oct 30.

PMID:
25359495
21.

Apelin counteracts vasopressin-induced water reabsorption via cross talk between apelin and vasopressin receptor signaling pathways in the rat collecting duct.

Hus-Citharel A, Bodineau L, Frugière A, Joubert F, Bouby N, Llorens-Cortes C.

Endocrinology. 2014 Nov;155(11):4483-93. doi: 10.1210/en.2014-1257. Epub 2014 Aug 26.

PMID:
25157454
22.

Biased signaling favoring gi over β-arrestin promoted by an apelin fragment lacking the C-terminal phenylalanine.

Ceraudo E, Galanth C, Carpentier E, Banegas-Font I, Schonegge AM, Alvear-Perez R, Iturrioz X, Bouvier M, Llorens-Cortes C.

J Biol Chem. 2014 Aug 29;289(35):24599-610. doi: 10.1074/jbc.M113.541698. Epub 2014 Jul 10.

23.

A new strategy for treating hypertension by blocking the activity of the brain renin-angiotensin system with aminopeptidase A inhibitors.

Gao J, Marc Y, Iturrioz X, Leroux V, Balavoine F, Llorens-Cortes C.

Clin Sci (Lond). 2014 Aug;127(3):135-48. doi: 10.1042/CS20130396. Review.

PMID:
24697296
24.

Structure-activity relationship studies toward the discovery of selective apelin receptor agonists.

Margathe JF, Iturrioz X, Alvear-Perez R, Marsol C, Riché S, Chabane H, Tounsi N, Kuhry M, Heissler D, Hibert M, Llorens-Cortes C, Bonnet D.

J Med Chem. 2014 Apr 10;57(7):2908-19. doi: 10.1021/jm401789v. Epub 2014 Mar 27.

PMID:
24625069
25.

Mechanisms involved in dual vasopressin/apelin neuron dysfunction during aging.

Sauvant J, Delpech JC, Palin K, De Mota N, Dudit J, Aubert A, Orcel H, Roux P, Layé S, Moos F, Llorens-Cortes C, Nadjar A.

PLoS One. 2014 Feb 5;9(2):e87421. doi: 10.1371/journal.pone.0087421. eCollection 2014.

26.

Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug.

Balavoine F, Azizi M, Bergerot D, De Mota N, Patouret R, Roques BP, Llorens-Cortes C.

Clin Pharmacokinet. 2014 Apr;53(4):385-95. doi: 10.1007/s40262-013-0125-y.

PMID:
24337978
27.

An abnormal apelin/vasopressin balance may contribute to water retention in patients with the syndrome of inappropriate antidiuretic hormone (SIADH) and heart failure.

Blanchard A, Steichen O, De Mota N, Curis E, Gauci C, Frank M, Wuerzner G, Kamenicky P, Passeron A, Azizi M, Llorens-Cortes C.

J Clin Endocrinol Metab. 2013 May;98(5):2084-9. doi: 10.1210/jc.2012-3794. Epub 2013 Mar 20.

PMID:
23515451
28.

Inhibition of brain angiotensin III attenuates sympathetic hyperactivity and cardiac dysfunction in rats post-myocardial infarction.

Huang BS, Ahmad M, White RA, Marc Y, Llorens-Cortes C, Leenen FH.

Cardiovasc Res. 2013 Mar 1;97(3):424-31. doi: 10.1093/cvr/cvs420. Epub 2012 Dec 19.

PMID:
23257024
29.

Apelin and vasopressin: two work better than one.

Llorens-Cortes C, Moos F.

J Neuroendocrinol. 2012 Jul;24(7):1085-6. doi: 10.1111/j.1365-2826.2012.02316.x.

PMID:
22712789
30.

Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats.

Marc Y, Gao J, Balavoine F, Michaud A, Roques BP, Llorens-Cortes C.

Hypertension. 2012 Aug;60(2):411-8. doi: 10.1161/HYPERTENSIONAHA.112.190942. Epub 2012 Jun 18.

PMID:
22710644
31.

Apelin in the control of body fluid homeostasis and cardiovascular functions.

Galanth C, Hus-Citharel A, Li B, Llorens-Cortès C.

Curr Pharm Des. 2012;18(6):789-98. Review.

PMID:
22236125
32.

Apelin and the proopiomelanocortin system: a new regulatory pathway of hypothalamic α-MSH release.

Reaux-Le Goazigo A, Bodineau L, De Mota N, Jeandel L, Chartrel N, Knauf C, Raad C, Valet P, Llorens-Cortes C.

Am J Physiol Endocrinol Metab. 2011 Nov;301(5):E955-66. doi: 10.1152/ajpendo.00090.2011. Epub 2011 Aug 16.

33.

Ghrelin and obestatin modulate growth hormone-releasing hormone release and synaptic inputs onto growth hormone-releasing hormone neurons.

Feng DD, Yang SK, Loudes C, Simon A, Al-Sarraf T, Culler M, Alvear-Perez R, Llorens-Cortes C, Chen C, Epelbaum J, Gardette R.

Eur J Neurosci. 2011 Sep;34(5):732-44. doi: 10.1111/j.1460-9568.2011.07787.x. Epub 2011 Jul 21.

PMID:
21777303
34.

The role of the brain renin-angiotensin system in hypertension: implications for new treatment.

Marc Y, Llorens-Cortes C.

Prog Neurobiol. 2011 Oct;95(2):89-103. doi: 10.1016/j.pneurobio.2011.06.006. Epub 2011 Jul 7. Review.

PMID:
21763394
35.

Data supporting a new physiological role for brain apelin in the regulation of hypothalamic oxytocin neurons in lactating rats.

Bodineau L, Taveau C, Lê Quan Sang HH, Osterstock G, Queguiner I, Moos F, Frugière A, Llorens-Cortes C.

Endocrinology. 2011 Sep;152(9):3492-503. doi: 10.1210/en.2011-0206. Epub 2011 Jul 5.

PMID:
21733827
36.

The RFamide neuropeptide 26RFa and its role in the control of neuroendocrine functions.

Chartrel N, Alonzeau J, Alexandre D, Jeandel L, Alvear-Perez R, Leprince J, Boutin J, Vaudry H, Anouar Y, Llorens-Cortes C.

Front Neuroendocrinol. 2011 Oct;32(4):387-97. doi: 10.1016/j.yfrne.2011.04.001. Epub 2011 Apr 20. Review.

PMID:
21530572
37.

Central apelin controls glucose homeostasis via a nitric oxide-dependent pathway in mice.

Duparc T, Colom A, Cani PD, Massaly N, Rastrelli S, Drougard A, Le Gonidec S, Moulédous L, Frances B, Leclercq I, Llorens-Cortes C, Pospisilik JA, Delzenne NM, Valet P, Castan-Laurell I, Knauf C.

Antioxid Redox Signal. 2011 Sep 15;15(6):1477-96. doi: 10.1089/ars.2010.3454. Epub 2011 May 25.

PMID:
21395477
38.

By interacting with the C-terminal Phe of apelin, Phe255 and Trp259 in helix VI of the apelin receptor are critical for internalization.

Iturrioz X, Gerbier R, Leroux V, Alvear-Perez R, Maigret B, Llorens-Cortes C.

J Biol Chem. 2010 Oct 15;285(42):32627-37. doi: 10.1074/jbc.M110.127167. Epub 2010 Jul 30.

39.

Multiple cross talk between angiotensin II, bradykinin, and insulin signaling in the cortical thick ascending limb of rat kidney.

Hus-Citharel A, Bouby N, Iturrioz X, Llorens-Cortes C.

Endocrinology. 2010 Jul;151(7):3181-94. doi: 10.1210/en.2009-1237. Epub 2010 May 12.

PMID:
20463058
40.

[Contribution of apelin to water balance, blood glucose control, and cardiovascular functions].

Bodineau L, Hus-Citharel A, Llorens-Cortes C.

Ann Endocrinol (Paris). 2010 Sep;71(4):249-56. doi: 10.1016/j.ando.2010.03.004. Epub 2010 Apr 22. French.

PMID:
20416860
41.

Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist.

Iturrioz X, Alvear-Perez R, De Mota N, Franchet C, Guillier F, Leroux V, Dabire H, Le Jouan M, Chabane H, Gerbier R, Bonnet D, Berdeaux A, Maigret B, Galzi JL, Hibert M, Llorens-Cortes C.

FASEB J. 2010 May;24(5):1506-17. doi: 10.1096/fj.09-140715. Epub 2009 Dec 29.

PMID:
20040517
42.

Identification of threonine 348 as a residue involved in aminopeptidase A substrate specificity.

Claperon C, Banegas-Font I, Iturrioz X, Rozenfeld R, Maigret B, Llorens-Cortes C.

J Biol Chem. 2009 Apr 17;284(16):10618-26. doi: 10.1074/jbc.M806783200. Epub 2009 Feb 19.

43.

Opposite potentiality of hypothalamic coexpressed neuropeptides, apelin and vasopressin in maintaining body-fluid homeostasis.

Llorens-Cortes C, Moos F.

Prog Brain Res. 2008;170:559-70. doi: 10.1016/S0079-6123(08)00443-3.

PMID:
18655909
44.

Asp218 participates with Asp213 to bind a Ca2+ atom into the S1 subsite of aminopeptidase A: a key element for substrate specificity.

Claperon C, Rozenfeld R, Iturrioz X, Inguimbert N, Okada M, Roques B, Maigret B, Llorens-Cortes C.

Biochem J. 2008 Nov 15;416(1):37-46. doi: 10.1042/BJ20080471.

PMID:
18598240
45.

Effect of apelin on glomerular hemodynamic function in the rat kidney.

Hus-Citharel A, Bouby N, Frugière A, Bodineau L, Gasc JM, Llorens-Cortes C.

Kidney Int. 2008 Aug;74(4):486-94. doi: 10.1038/ki.2008.199. Epub 2008 May 28.

46.

Human brain aminopeptidase A: biochemical properties and distribution in brain nuclei.

de Mota N, Iturrioz X, Claperon C, Bodineau L, Fassot C, Roques BP, Palkovits M, Llorens-Cortes C.

J Neurochem. 2008 Jul;106(1):416-28. doi: 10.1111/j.1471-4159.2008.05402.x. Epub 2008 Apr 1.

47.

Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension.

Bodineau L, Frugière A, Marc Y, Inguimbert N, Fassot C, Balavoine F, Roques B, Llorens-Cortes C.

Hypertension. 2008 May;51(5):1318-25. doi: 10.1161/HYPERTENSIONAHA.107.098772. Epub 2008 Mar 24.

PMID:
18362226
48.

Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli.

Azizi M, Iturrioz X, Blanchard A, Peyrard S, De Mota N, Chartrel N, Vaudry H, Corvol P, Llorens-Cortes C.

J Am Soc Nephrol. 2008 May;19(5):1015-24. doi: 10.1681/ASN.2007070816. Epub 2008 Feb 13. No abstract available.

49.

Jacques Benoit lecture: the neuroendocrine view of the angiotensin and apelin systems.

Llorens-Cortes C, Kordon C.

J Neuroendocrinol. 2008 Mar;20(3):279-89. doi: 10.1111/j.1365-2826.2007.01642.x. Epub 2008 Jan 11.

PMID:
18194430
50.

Aminopeptidase A inhibitors as centrally acting antihypertensive agents.

Bodineau L, Frugière A, Marc Y, Claperon C, Llorens-Cortes C.

Heart Fail Rev. 2008 Sep;13(3):311-9. doi: 10.1007/s10741-007-9077-3. Epub 2008 Jan 3. Review.

PMID:
18175217

Supplemental Content

Loading ...
Support Center